SCHEMBL4013435

SCHEMBL4013435

O=[N+]([O-])c1ccc2[nH]nc(-c3ccc(Cl)cc3)c2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.74
HPGD P15428 2/20 0.74
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
POLB P06746 2/20 0.53
PKM P14618 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 1/20 0.51
NPBWR1 P48145 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
OPRK1 P41145 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
MAP2K4 P45985 1/20 0.44
ABCC8 Q09428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568062 0.86 MAPT (0.74) MAPTHPGDKMT2AMEN1RAB9A
SCHEMBL27648257 0.86 MAPT (0.74) MAPTHPGDKMT2AMEN1NPC1
SCHEMBL5377226 0.86 MAPT (0.94) MAPTHPGDKMT2ANPC1RAB9A
SCHEMBL4007995 0.85 MAPT (1.00) MAPTHPGDKMT2ANPC1RAB9A
SCHEMBL5381604 0.85 MAPT (0.69) MAPTHPGDKMT2AMEN1NPC1
SCHEMBL5382206 0.82 MAPT (0.69) MAPTHPGDKMT2AMEN1NPC1
SCHEMBL5378145 0.81 MAPT (0.81) MAPTHPGDKMT2AMEN1RAB9A
SCHEMBL760760 0.80 MAPT (0.61) MAPTHPGDKMT2AMEN1POLB
SCHEMBL5381610 0.80 MAPT (0.66) MAPTHPGDNPBWR1CA12CA9
SCHEMBL20379652 0.80 MAPT (0.66) MAPTHPGDKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAPT 2426/4885HPGD 1246/4885KMT2A 1089/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAPT 3070/4885HPGD 1303/4885KMT2A 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.